Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
HEXVIX hexaminolevulinate (as hydrochloride) 85 mg powder for intravesical solution plus diluent, Juno Pharmaceuticals Pty Ltd, CON-917
Product name
HEXVIX hexaminolevulinate (as hydrochloride) 85 mg powder for intravesical solution plus diluent
Sponsor name
Juno Pharmaceuticals Pty Ltd
Batches
HA2904
Consent start
Consent no.
CON-917
Standard
Paragraph 8(1)(h) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines (TGO 91)
Non-compliance with standard
The product does not conform to the requirements of paragraph 8(1)(h) of
Therapeutic Goods Order No. 91 - Standard for labels of prescription and related
medicines (TGO 91), in that the product displays previously approved storage
conditions 'Store below 25°C' instead of the current approved storage conditions
'Store below 30°C'.
Conditions imposed
The labels to which this consent applies are those supplied with the letter
dated 1 February 2022.
Therapeutic product type
Prescription medicines